No worries if you cannot answer for disclosure reasons, but I am curious where you got the estimations from? Be looking at around $1 million revenues in Oz, that pale in comparison to the some $30 million from the US and $15 million in EU on that basis.
Throw in CelGro Nerve revenues and initial and milestone payments from a J&J partnership and revenues could go exponential pretty quickly, as will the share price of course....these bio-techs prospects are like call options from an investment perspective, one day apt to take off.
FDA significance, page-405
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $78.59M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 37.0¢ | $10.96K | 29.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 72974 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 32023 | 1 |
View Market Depth
| Last trade - 11.09am 15/08/2024 (20 minute delay) ? |
| OCC (ASX) Chart |